196 related articles for article (PubMed ID: 21499162)
1. Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Hanaoka K; Hosono M; Usami K; Tatsumi Y; Yamazoe Y; Komeya Y; Tsuchiya N; Ishii K; Sumita M
Nucl Med Commun; 2011 Aug; 32(8):678-83. PubMed ID: 21499162
[TBL] [Abstract][Full Text] [Related]
2. Decreased brain FDG uptake in patients with extensive non-Hodgkin's lymphoma lesions.
Hanaoka K; Hosono M; Shimono T; Usami K; Komeya Y; Tsuchiya N; Yamazoe Y; Ishii K; Tatsumi Y; Sumita M
Ann Nucl Med; 2010 Dec; 24(10):707-11. PubMed ID: 20824395
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.
Sugawara Y; Fisher SJ; Zasadny KR; Kison PV; Baker LH; Wahl RL
J Clin Oncol; 1998 Jan; 16(1):173-80. PubMed ID: 9440740
[TBL] [Abstract][Full Text] [Related]
4. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow.
Kazama T; Swanston N; Podoloff DA; Macapinlac HA
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1406-11. PubMed ID: 16133379
[TBL] [Abstract][Full Text] [Related]
5. Inhomogeneous bone marrow uptake caused by G-CSF mimics multiple bone metastases on FDG-PET.
Nakamoto Y; Suga T; Hara T; Ishizu K; Togashi K
Clin Nucl Med; 2010 Feb; 35(2):74-6. PubMed ID: 20090448
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the interval between G-CSF therapy and F-18 FDG PET imaging in children and young adults receiving chemotherapy for sarcoma.
Trout AT; Sharp SE; Turpin BK; Zhang B; Gelfand MJ
Pediatr Radiol; 2015 Jul; 45(7):1001-6. PubMed ID: 25646737
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
Zhang Q; Tian T; Wang L; Qiu H; Li D
Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
[TBL] [Abstract][Full Text] [Related]
8.
Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
[TBL] [Abstract][Full Text] [Related]
9. Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT.
Murata Y; Kubota K; Yukihiro M; Ito K; Watanabe H; Shibuya H
Nucl Med Biol; 2006 Nov; 33(8):999-1004. PubMed ID: 17127173
[TBL] [Abstract][Full Text] [Related]
10. [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF].
Ruiz-Hernández G; Scaglione C; Delgado-Bolton RC; Gutiérrez-García A; Madero L; Jiménez-Vicioso A; Carreras-Delgado JL
Rev Esp Med Nucl; 2004; 23(2):124-6. PubMed ID: 15000944
[TBL] [Abstract][Full Text] [Related]
11. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Eur J Haematol; 2015 Jul; 95(1):83-9. PubMed ID: 25537478
[TBL] [Abstract][Full Text] [Related]
12. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
13. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?
Salaun PY; Gastinne T; Bodet-Milin C; Campion L; Cambefort P; Moreau A; Le Gouill S; Berthou C; Moreau P; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1813-21. PubMed ID: 19499219
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
15. Association Between Time Since Administration of Pegylated G-CSF (Pegfilgrastim) and Bone Marrow Uptake on FDG PET/CT: Determination of a Minimum Interval.
Minamimoto R; Baratto L; Iagaru A
AJR Am J Roentgenol; 2022 Feb; 218(2):351-358. PubMed ID: 34467784
[No Abstract] [Full Text] [Related]
16. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results.
Sugawara Y; Zasadny KR; Kison PV; Baker LH; Wahl RL
J Nucl Med; 1999 Sep; 40(9):1456-62. PubMed ID: 10492365
[TBL] [Abstract][Full Text] [Related]
17. Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Nucl Med Commun; 2016 Jan; 37(1):23-9. PubMed ID: 26440567
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of bone marrow
Lee JW; Lee SC; Kim HJ; Lee SM
Hell J Nucl Med; 2017; 20(1):17-25. PubMed ID: 28315904
[TBL] [Abstract][Full Text] [Related]
20. Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?
Çetin G; Çıkrıkçıoğlu MA; Özkan T; Karatoprak C; Ar MC; Eşkazan AE; Ayer M; Cerit A; Gözübenli K; Uysal BB; Erdem S; Ergül N; Tatar G; Çermik TF
Turk J Haematol; 2015 Sep; 32(3):213-9. PubMed ID: 25912844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
